Investing.com -- Entera Bio Ltd. (NASDAQ:ENTX) stock rose 3.5% in Thursday’s premarket trading following the company’s presentation of new clinical data from its Phase 2 trial of EB613, an oral ...

Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women 10 years ...

Researchers said infrequent zoledronate infusions could be an attractive, lifelong therapy for women at low-risk for fracture ...

The Dubai Civil Aviation Authority (DCAA) concluded the inaugural edition of the Aviation Safety Transformation Summit 2025, ...

The Supreme Organising Committee of the Open Masters Games Abu Dhabi 2026 has announced the launch of the Open Masters Games ...

This recipe explores how to smoke a tomahawk ribeye steak using the reverse sear method to achieve optimal tenderness and ...

New review finds yogurt provides nutrients but offers minimal real-world benefits for bone strength or fracture prevention in ...

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

The Brisbane Tigers completed a flawless 2025 season by securing the BMD Premiership title with a 22–6 win over the Burleigh Bears at Kayo Stadium, Redcliffe. The Tigers went through the season ...

Entera Bio (ENTX) reported new clinical data from a post-hoc analysis of its Phase 2 trial of EB613, at the 2025 North American Menopause Society ...

US President Donald Trump addressed the Israeli Knesset in a historic and emotional speech following the release of hostages ...